



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## CTPI-2

Item No. 36933

**CAS Registry No.:** 68003-38-3  
**Formal Name:** 2-[[[4-chloro-3-nitrophenyl]sulfonyl]amino]-benzoic acid  
**MF:** C<sub>13</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>6</sub>S  
**FW:** 356.7  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

CTPI-2 is supplied as a solid. A stock solution may be made by dissolving the CTPI-2 in the solvent of choice, which should be purged with an inert gas. CTPI-2 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of CTPI-2 in these solvents is approximately 5 and 2 mg/ml, respectively.

### Description

CTPI-2 is an inhibitor of the mitochondrial citrate transporter, also known as SLC25A1.<sup>1</sup> It decreases the oxygen consumption rate (OCR) in tumor spheres isolated from patients with non-small cell lung cancer (NSCLC) and inhibits the invasion of lung cancer stem cells *in vitro*. CTPI-2 (50 μM) acts synergistically with cisplatin (Item No. 13119) to reduce the viability of cisplatin-resistant patient-derived NSCLC cells. It reverses increases in body weight, steatosis, and fasting blood glucose levels in a mouse model of high fat diet-induced non-alcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg.<sup>2</sup>

### References

1. Fernandez, H.R., Gadre, S.M., Tan, M., *et al.* The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. *Cell Death Differ.* **25(7)**, 1239-1258 (2018).
2. Tan, M., Mosaoa, R., Graham, G.T., *et al.* Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. *Cell Death Differ.* **27(7)**, 2143-2157 (2020).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM